LICENSE REVENUES - Narrative (Details) $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended
	Nov. 30, 2024 USD ($)	May 31, 2024 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2025 USD ($) obligation	Jun. 30, 2024 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2020 program
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items
Nonrefundable, payment			$ 1,300
Maximum potential milestone payments			41,250		$ 41,250
Revenue, number of performance obligation, | obligation					1
Amount allocated to performance obligation			1,300
Total revenue			1,300	$ 100	$ 1,300	$ 100
License Fee Revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items
Total revenue			1,300	100	1,300	100
Scithera License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items
Nonrefundable, payment			1,300		1,300
Scithera License Agreement | License Fee Revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items
Revenue recognized related to performance obligation			1,300		1,300
2seventy bio, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items
Development milestone payment receivable							$ 51,500
2seventy bio, Inc. | Initial Programs
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items
Number of program related to collaborative agreement | program								2
2seventy bio, Inc. | Additional Programs
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items
Number of program related to collaborative agreement | program								8
Regeneron Pharmaceuticals, Inc. | Initial Programs, Program 3
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items
Nonrefundable, upfront payment	$ 100	$ 100
Nonrefundable, upfront payment, period (in months)	6 months
Regeneron Pharmaceuticals, Inc. | License Fee Revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items
Total revenue			$ 0	$ 100	$ 0	$ 100